Mechanistic basis of bacteriophages for the decolonization of vancomycin resistant enterococci in the intestine.
噬菌体对肠道内万古霉素耐药肠球菌去定植的机制基础。
基本信息
- 批准号:10228669
- 负责人:
- 金额:$ 37.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-14 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:Antibiotic ResistanceAntibiotic TherapyAntibioticsBacteremiaBacteriaBacterial Antibiotic ResistanceBacterial InfectionsBacteriophagesBindingBiological ProductsBlood CirculationCell WallClinicCommunitiesDevelopmentDrug resistanceEnterococcusEnterococcus faecalisEnvironmentEvolutionFutureGenomeGenome StabilityGenomicsGerm-FreeGoalsGram-Positive BacteriaHabitatsHospitalsHumanIn VitroIncidenceIndividualInfectionIntestinesKnowledgeLeadMediatingModelingMolecularMolecular GeneticsMulti-Drug ResistanceMultiple Bacterial Drug ResistanceMusMutationNatural ImmunityNosocomial InfectionsOral AdministrationOutcomePhage ReceptorsPhysiologicalPopulationPredatory BehaviorProcessResistanceResortSepsisSiteSpecificityTherapeuticTherapeutic InterventionTissuesVancomycinVancomycin resistant enterococcusVirusbacterial fitnessbacterial resistancebasecombatexperienceexperimental studygenome sequencinggut colonizationgut microbiotain vivoinsightmicrobiotanovelnovel therapeutic interventionnovel therapeuticsopportunistic pathogenpathogenic bacteriaplasmid DNApressurereceptorreceptor functionresistant strainstandard of caretraittreatment strategywhole genome
项目摘要
Project Summary/Abstract
The incidence of multidrug resistant (MDR) bacterial infections is rising. This is particularly relevant for the Gram-
positive bacterium Enterococcus faecalis, an opportunistic pathogen and leading cause of nosocomial
bacteremia. The rise in MDR E. faecalis infections is largely attributed to their ability to resist many antibiotics
including antibiotics of “last resort”, such as vancomycin. E. faecalis is a native inhabitant of the human intestinal
tract which serves as a major reservoir of MDR E. faecalis. Antibiotic depletion of the intestinal microbiota can
facilitate blooms of E. faecalis leading to their enhanced dissemination to the bloodstream and other tissue sites.
In many cases overgrowth of intestinal enterococci is dominated by vancomycin resistant enterococci (VRE)
which severely limits available treatment options. With increasing VRE infections worldwide, it is imperative that
new strategies for therapeutic intervention are explored. An alternative to traditional antibiotics is the use of
biological agents for the treatment of drug resistant bacterial infections. One approach is harnessing
bacteriophages (phages) that infect and kill bacteria. Although phages may hold promise as next generation
therapeutics, we know little of the basic principles of phage infection processes in vivo and how the mammalian
host environment influences phage-bacteria interactions. This project investigates the use of phages for the
decolonization of VRE within its natural intestinal habitat. Using a combination of mouse intestinal colonization
models, molecular genetics and whole genome sequencing, we aim to gain mechanistic insight into how
intestinal selective pressures influence the infectivity and genome evolution of phages during phage-mediated
VRE decolonization. To achieve this goal we will execute three specific aims: 1) Define the intestinal selective
pressures that dictate phage-mediated E. faecalis decolonization, 2) Determine the long-term stability and
genomic evolution of E. faecalis phages in the intestine, and 3) Determine cognate receptors for diverse
E. faecalis phages and delineate receptor function. Understanding intestinal selective pressures and
molecular mechanisms of enterococcal phage infection in vivo will aid in the development of novel phage
therapeutics for the decolonization of enterococci recalcitrant to conventional antibiotics.
项目总结/摘要
多药耐药(MDR)细菌感染的发病率正在上升。这一点对于Gram来说尤为重要。
粪肠球菌是一种条件致病菌,是导致医院感染的主要原因。
菌血症MDR E.粪菌感染主要归因于它们抵抗许多抗生素的能力
包括抗生素的“最后手段”,如万古霉素。E.粪菌是人类肠道的原住民
作为MDR E的主要储存库的通道。粪便肠道菌群的抗生素消耗可以
促进E.粪便,导致其向血流和其他组织部位的传播增强。
在许多情况下,肠球菌的过度生长主要是万古霉素耐药肠球菌(VRE)
这严重限制了可用的治疗选择。随着全球VRE感染的增加,
探索了治疗干预的新策略。传统抗生素的替代品是使用
用于治疗抗药性细菌感染的生物制剂。一种方法是利用
感染并杀死细菌的噬菌体。尽管作为下一代,
虽然我们对噬菌体体内感染过程的基本原理以及哺乳动物如何感染噬菌体的方法知之甚少,
宿主环境影响噬菌体-细菌相互作用。本项目研究了将生物柴油用于
VRE在其自然肠道栖息地内的非殖民化。利用小鼠肠道定植
模型,分子遗传学和全基因组测序,我们的目标是获得机制的洞察如何
肠道选择性压力影响噬菌体介导的大肠杆菌的感染性和基因组进化
VRE非殖民化。为了实现这一目标,我们将执行三个具体目标:1)定义肠道选择性
压力决定噬菌体介导的E.粪便去殖民化,2)确定长期稳定性,
E.肠中的粪肠球菌,和3)确定不同的同源受体
E.粪便排泄物和描绘受体功能。了解肠道选择性压力,
体内肠球菌噬菌体感染的分子机制将有助于开发新的噬菌体
用于使柠檬酸肠球菌对常规抗生素去殖民化的治疗剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Breck A Duerkop其他文献
Breck A Duerkop的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Breck A Duerkop', 18)}}的其他基金
Mechanistic basis of bacteriophages for the decolonization of vancomycin resistant enterococci in the intestine.
噬菌体对肠道内万古霉素耐药肠球菌去定植的机制基础。
- 批准号:
10456852 - 财政年份:2018
- 资助金额:
$ 37.76万 - 项目类别:
Mechanistic basis of bacteriophages for the decolonization of vancomycin resistant enterococci in the intestine
噬菌体在肠道内去定植耐万古霉素肠球菌的机制基础
- 批准号:
10810149 - 财政年份:2018
- 资助金额:
$ 37.76万 - 项目类别:
The contribution of bacteriophages to host-microbe interactions in the intestine
噬菌体对肠道宿主-微生物相互作用的贡献
- 批准号:
9408038 - 财政年份:2014
- 资助金额:
$ 37.76万 - 项目类别:
The contribution of bacteriophages to host-microbe interactions in the intestine
噬菌体对肠道宿主-微生物相互作用的贡献
- 批准号:
8920567 - 财政年份:2014
- 资助金额:
$ 37.76万 - 项目类别:
The contribution of bacteriophages to host-microbe interactions in the intestine
噬菌体对肠道宿主-微生物相互作用的贡献
- 批准号:
8747735 - 财政年份:2014
- 资助金额:
$ 37.76万 - 项目类别:
The contribution of bacteriophages to host-microbe interactions in the intestine
噬菌体对肠道宿主-微生物相互作用的贡献
- 批准号:
9341250 - 财政年份:2014
- 资助金额:
$ 37.76万 - 项目类别:
Interactions of a commensal bacterium with the intestinal mucosal surface
共生细菌与肠粘膜表面的相互作用
- 批准号:
8296343 - 财政年份:2010
- 资助金额:
$ 37.76万 - 项目类别:
Interactions of a commensal bacterium with the intestinal mucosal surface
共生细菌与肠粘膜表面的相互作用
- 批准号:
8096562 - 财政年份:2010
- 资助金额:
$ 37.76万 - 项目类别:
Interactions of a commensal bacterium with the intestinal mucosal surface
共生细菌与肠粘膜表面的相互作用
- 批准号:
8003030 - 财政年份:2010
- 资助金额:
$ 37.76万 - 项目类别:
相似海外基金
SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
- 批准号:
2213034 - 财政年份:2023
- 资助金额:
$ 37.76万 - 项目类别:
Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
- 批准号:
10645528 - 财政年份:2023
- 资助金额:
$ 37.76万 - 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
- 批准号:
10736285 - 财政年份:2023
- 资助金额:
$ 37.76万 - 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
- 批准号:
10603486 - 财政年份:2023
- 资助金额:
$ 37.76万 - 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 37.76万 - 项目类别:
Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
- 批准号:
422034 - 财政年份:2020
- 资助金额:
$ 37.76万 - 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
- 批准号:
nhmrc : 1197866 - 财政年份:2020
- 资助金额:
$ 37.76万 - 项目类别:
Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
- 批准号:
2241853 - 财政年份:2019
- 资助金额:
$ 37.76万 - 项目类别:
Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
- 批准号:
18K07106 - 财政年份:2018
- 资助金额:
$ 37.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
- 批准号:
9788269 - 财政年份:2018
- 资助金额:
$ 37.76万 - 项目类别: